CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Adjuvant chemotherapy in resected colon cancer: When, how and how long?

Gelibter, Alain J., Caponnetto, Salvatore, Urbano, Federica, Emiliani, Alessandra, Scagnoli, Simone, Sirgiovanni, Grazia, Napoli, Valerio M., Cortesi, Enrico·2019·Surgical Oncology
DOI 10.1016/j.suronc.2019.06.003
Open this paper in CoChat — free account

Abstract

The benefit of adjuvant chemotherapy has been clearly established in the adjuvant setting for node-positive colon cancer. A number of trials in the adjuvant setting have analyzed the efficacy of multiple-agent combinations, including irinotecan, oxaliplatin, bevacizumab and cetuximab. Only oxaliplatin added to fluorouracil/capecitabine has been shown to be superior beyond a fluropyrimidine alone in the adjuvant setting. As such, standard treatment options include fluorouracil (FU) or capecitabine with or without oxaliplatin. However, oxaliplatin is associated with cumulative dose-dependent neurotoxicity, characterized by distal or perioral paresthesias or dysesthesias; for this reason, in this review we discuss the results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) trial. The IDEA trail is the largest prospective clinical trial ever conducted in colorectal cancer, wherein patients were treated with either 3 months or 6 months of adjuvant chemotherapy. In the era of cancer gene expression-based subtyping, the Colorectal Cancer Subtyping Consortium has proposed a four-subgroup molecular classification system for colorectal cancer, consisting of CMS1 (immune), CMS2 (canonical), CMS3 (metabolic) and CMS4 (mesenchymal). In this review, we present and analyze the available data on efficacy and toxicity of the combination regimen approved for treatment of resected colon cancer, and discuss the questions of when, how and how long we need to treat such pa…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.suronc.2019.06.003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 50

  1. Macdonald John, 1999, Adjuvant therapy of colon cancer, Ca - Cancer J. Clin., 49, 202
  2. Haller, 2005, Phase III study of fluorouracil, LV, and levamisole in high-risk stage II and III colon cancer: final report of intergroup 0089, J. Clin. Oncol., 23, 8671, 10.1200/JCO.2004.00.5686 · DOI
  3. Wolmark, 1999, J. Clin. Oncol., 17, 3553, 10.1200/JCO.1999.17.11.3553 · DOI
  4. André, 2007, Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and LV as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1, J. Clin. Oncol., 25, 3732, 10.1200/JCO.2007.12.2234 · DOI
  5. André, 2001, Semin. Oncol., 28, 35, 10.1016/S0093-7754(01)90250-7 · DOI
  6. Twelves, 2012, Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy, Ann. Oncol., 23, 1190, 10.1093/annonc/mdr366 · DOI
  7. Moertel, 1995, Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer, J. Clin. Oncol., 13, 2936, 10.1200/JCO.1995.13.12.2936 · DOI
  8. Schippinger, 2007, Austrian Breast and Colorectal Cancer Study Group. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and LV in patients with stage II colon cancer, Br. J. Canc., 97, 1021, 10.1038/sj.bjc.6604011 · DOI
  9. Giacchetti, 2000, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-LV as first-line treatment of metastatic colorectal cancer, J. Clin. Oncol., 18, 136, 10.1200/JCO.2000.18.1.136 · DOI
  10. de Gramont, 2000, LV and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J. Clin. Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
  11. Saltz, 2007, Irinotecan fluorouracil plus LV is not superior to fluorouracil plus LV alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J. Clin. Oncol., 25, 3456, 10.1200/JCO.2007.11.2144 · DOI
  12. Allegra, 2013, Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial, J. Clin. Oncol., 31, 359, 10.1200/JCO.2012.44.4711 · DOI
  13. de Gramont, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol., 13, 1225, 10.1016/S1470-2045(12)70509-0 · DOI · Paper page
  14. Alberts, 2012, Effect of oxaliplatin, fluorouracil, and LV with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, J. Am. Med. Assoc., 307, 1383, 10.1001/jama.2012.385 · DOI
  15. Andre, 2004, Oxaliplatin, fluorouracil, and LV as adjuvant treatment for colon cancer, N. Engl. J. Med., 350, 2343e2351, 10.1056/NEJMoa032709 · DOI
  16. Tournigand, 2012, J. Clin. Oncol., 30, 3353, 10.1200/JCO.2012.42.5645 · DOI
  17. Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and LV as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J. Clin. Oncol., 27, 3109, 10.1200/JCO.2008.20.6771 · DOI
  18. Yothers, 2011, Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J. Clin. Oncol., 29, 3768, 10.1200/JCO.2011.36.4539 · DOI
  19. Kuebler, 2007, Oxaliplatin combined with weekly bolus fluorouracil and LV as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J. Clin. Oncol., 25, 2198, 10.1200/JCO.2006.08.2974 · DOI
  20. Schmoll, 2007, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients, J. Clin. Oncol., 25, 102, 10.1200/JCO.2006.08.1075 · DOI
  21. Schmoll, 2015, Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/LV (5-FU/LV) as adjuvant therapy for stage III colon cancer: survival follow-up of study NO16968 (XELOXA), J. Clin. Oncol., 33, 3733, 10.1200/JCO.2015.60.9107 · DOI
  22. Pectasides, 2015, BMC Canc., 15, 384, 10.1186/s12885-015-1406-7 · DOI
  23. Kidwell, 2012, Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and LV as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 118, 5614, 10.1002/cncr.27593 · DOI
  24. Mols, 2013, Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry, J. Clin. Oncol., 31, 2699, 10.1200/JCO.2013.49.1514 · DOI
  25. Sobrero, 2017, FOLFOX4/XELOX in stage II–III colon cancer: efficacy results of the Italian three or six colon adjuvant (TOSCA) trial, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.3501 · DOI
  26. Yoshino, 2017, Efficacy of 3 versus 6 months of oxaliplatin-basedadjuvant chemotherapy for stage III colon cancer (CC): results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) collaboration, Ann. Oncol., 10.1093/annonc/mdx440.017 · DOI
  27. Andrè, 2018, Three versus 6 Months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, phase III trial, J. Clin. Oncol., 36, 1469, 10.1200/JCO.2017.76.0355 · DOI
  28. Sinicrope, 2013, Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy, J. Clin. Oncol., 31, 3664, 10.1200/JCO.2013.48.9591 · DOI
  29. Thibodeau, 1993, Microsatellite instability in cancer of the proximal colon, Science, 260, 816, 10.1126/science.8484122 · DOI
  30. Deng, 2004, BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin. Cancer Res., 10, 191, 10.1158/1078-0432.CCR-1118-3 · DOI
  31. Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J. Clin. Oncol., 28, 3219, 10.1200/JCO.2009.27.1825 · DOI · Paper page
  32. Gavin, 2013, Colon cancer mutation: prognosis/prediction–response, Clin. Cancer Res., 19, 1301, 10.1158/1078-0432.CCR-13-0020 · DOI
  33. Gavin, 2013, Colon cancer mutation: prognosis/prediction--response, Clin. Cancer Res., 19, 1301, 10.1158/1078-0432.CCR-13-0020 · DOI
  34. Bertagnolli, 2011, Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803, J. Clin. Oncol., 29, 3153, 10.1200/JCO.2010.33.0092 · DOI
  35. Popat, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, J. Clin. Oncol., 23, 609, 10.1200/JCO.2005.01.086 · DOI
  36. Carethers, 1999, Mismatch repair proficiency and in vitro response to 5-fluorouracil, Gastroenterology, 117, 123, 10.1016/S0016-5085(99)70558-5 · DOI
  37. Arnold, 2003, Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines, Int. J. Cancer, 106, 66, 10.1002/ijc.11176 · DOI · Paper page
  38. Des Guetz, 2009, Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis, Eur. J. Cancer, 45, 1890, 10.1016/j.ejca.2009.04.018 · DOI
  39. Kim, 2010, Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy, Cancer Chemother. Pharmacol., 66, 659, 10.1007/s00280-009-1206-3 · DOI
  40. André, 2014, Mosaic study: actualization of overall survival (os) with 10 years follow up and evaluation of braf. by gercor and mosaic investigators, Ann. Oncol., 25
  41. Zaanan, 2010, Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and LV with or without oxaliplatin, Ann. Oncol., 21, 772, 10.1093/annonc/mdp383 · DOI
  42. Klingbiel, 2015, Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, Ann. Oncol., 26, 126, 10.1093/annonc/mdu499 · DOI
  43. Taieb, 2016, Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with LV, Fluorouracil, and Oxaliplatin with or without Cetuximab: post hoc analysis of the PETACC-8 trial, JAMA Oncol, 2, 643, 10.1001/jamaoncol.2015.5225 · DOI
  44. Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J. Clin. Oncol., 28, 466, 10.1200/JCO.2009.23.3452 · DOI
  45. Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat. Med., 21, 1350, 10.1038/nm.3967 · DOI · Paper page
  46. Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 · DOI · Paper page
  47. Renfro, 2017, Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair proficient stage IIA colon cancer, Clin. Colorectal Cancer, 16, 23
  48. Gray, 2011, Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer, J. Clin. Oncol., 29, 4611, 10.1200/JCO.2010.32.8732 · DOI
  49. Yamanaka, 2016, 12-Gene recurrence Score assay stratifies the recurrence risk in stage II/III colon cancer with surgery alone: the SUNRISE study, J. Clin. Oncol., 34, 2906, 10.1200/JCO.2016.67.0414 · DOI
  50. Srivastava, 2014, Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients, Oncol., 19, 492, 10.1634/theoncologist.2013-0401 · DOI

Cited by

Sorted by citations

Metadata

Authors
Gelibter, A. J., Caponnetto, S., Urbano, F., Emiliani, A., Scagnoli, S., Sirgiovanni, G., Napoli, V. M., & Cortesi, E.
ORCID
Venue
Surgical Oncology
Publisher
Elsevier BV
Published
2019-09
Volume
30
Pages
100-107
ISSN
0960-7404
DOI
10.1016/j.suronc.2019.06.003
Cited by
75
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review